PA-SYNERGIS-SOFTWARE
30.3.2022 14:23:11 CEST | Business Wire | Press release
Synergis Software, a global leader in engineering document management and workflow solutions, is hosting a free live panel for engineering, operations, and IT leaders who want to learn how to overcome drawing management and collaboration chaos and create a more resilient, adaptable, and secure utility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220330005277/en/
The live 90-minute webinar will take place on Wednesday, April 6, 2022, at 2:00 p.m. EDT. The panel will be moderated by Scott Lamond, Vice President at Synergis Software with these guest panelists:
- Paul J. Melzen, P.E., Director, Eversource Substation Engineering & Design
- Blake Donley, Principal Systems Analyst, Great River Energy
- Bernie Voges, Senior Protection Engineer, Hoosier Energy
Discussion topics will include the advantages of a centralized platform for drawing management and collaboration, best practices, and lessons learned for implementation and user adoption. Attendees will gain insights that will help them:
- Align engineering, construction, field service, and operations
- Ensure fast access to the right version, day or night
- Eliminate expensive mistakes and outages
- Simplify collaboration and accelerate projects
- Capture tribal knowledge and secure digital assets
- Streamline compliance and drive standards
The live Q&A session will allow attendees to get their questions answered.
Register now to reserve your seat, and if you can't attend, register to receive a replay.
“Our utility customers know the hidden costs and inefficiencies of doing business without a centralized drawing management and collaboration solution that aligns engineering, field service, operations, and construction,” says Scott Lamond, vice president at Synergis Software. “With our Adept engineering document management solution, utilities will increase asset reliability, improve operational efficiency, reduce compliance and safety risk, and lower operating costs.”
Paul Melzen, director, Eversource substation engineering and design says, “In addition to configuration control, drawing management has become more and more critical to reliability and compliance. If the drawings don't represent what's in the field, it's just a human error trap."
“When the people in the field can’t find the correct drawing, it can result in more man-hours spent to resolve an issue, which can have a direct impact on our customers,” adds Melzen. “Moreover, if we're designing and bidding on a project using inaccurate drawings, we’re exposing ourselves to the risk of change orders from our engineering and construction contractors. Not only can these issues have significant cost impacts to the company, but they can also impact compliance, reliability and safety.”
Synergis Adept is a proven solution used by utility customers such as Con Edison, Northwestern Energy, San Diego Gas & Electric, Dominion Energy, Emera Companies, Lansing Board of Water and Light, California Water Authority, Platte River Authority, Turlock Irrigation District and more .
For further information on the webinar or to register, visit the event page event page. If you can't attend, register to receive the replay.
About Synergis Software
Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects your enterprise applications so your data and business processes flow seamlessly across your entire IT infrastructure.
Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, our commitment to clients is unwavering.
Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded.
About Eversource
Eversource (NYSE: ES), celebrated as a national leader for its corporate citizenship, is the #1 energy company in Newsweek’s list of America’s Most Responsible Companies for 2021 and recognized as one of America’s Most JUST Companies. The #1 energy efficiency provider in the nation, the company is empowering a clean energy future in the Northeast, with nationally recognized energy efficiency solutions and successful programs to integrate new clean energy resources like solar, offshore wind, electric vehicles, and battery storage, into the electric system.
About Great River Energy
Great River Energy (GRE) is wholesale power cooperative; our member-owners are 28 Minnesota electric distribution cooperatives. Individuals and businesses are members of those distribution cooperatives based on their geographic location.
As a Touchstone Energy Cooperative, GRE is a part of a nationwide alliance made of more than 750 electric cooperatives in 46 states.
About Hoosier Energy
Hoosier Energy serves 18-member electric cooperatives in central and southern Indiana and southeastern Illinois. Founded in 1949 and based in Bloomington, Indiana, Hoosier Energy is a generation and transmission electric cooperative providing wholesale power and services to member distribution cooperatives. Their portfolio includes coal, natural gas and renewable energy resources that deliver power through a nearly 1,700-mile transmission network.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005277/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom